Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs

  • Pieris Pharmaceuticals Inc PIRS decided to end work on Cinrebafusp alfa (PRS-343), a 4-1BB/HER2 anticalin-based bispecific, as part of a strategic pipeline prioritization to focus its resources.
  • The drug was slapped with an FDA clinical hold in July 2020
  • In August, Eli Lilly And Co LLY announced a trial collaboration to contribute its ramucirumab (Cyramza) and paclitaxel for the Phase 2 study in HER2-positive gastric cancer.
  • For the AstraZeneca plc AZN-partnered program, Pieris says its Big Pharma did a “reforecast” of the study to account for “global challenges” in recruiting patients because of COVID-19’s impact.
  • The companies are loosening the enrollment criteria and focusing on the 3 mg cohort for the efficacy readout. Topline results are slated for Q3 of 2023 after initially expecting the data this year.
  • After the results come in, Pieris can exercise a co-development option and could co-commercialize the drug in the U.S.
  • Pieris held a cash balance of $117.8 million. With the wind-down of the cinrebafusp alfa phase 2 trials and the expectation of modest near-term development milestones, the company believes operations are sufficiently funded into Q2 of 2024.
  • Price Action: PIRS shares are down 7.69% at $1.68 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsPenny StocksGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!